There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO 2 /FiO 2 increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (range 72–533, IQR 158–331) at day 7 after treatment with canakinumab ( p < 0.0001). Improvement of oxygen support category was observed in 61.4% of cases. Median duration of hospitalization following administration of canakinumab was 6 days (range 0–30, IQR 4–11). At 7 days, 58% of patients had been discharged and 12 (13.6%) had died. Significant differences between baseline and 7 days were observed for absolute lymphocyte counts (mean 0.60 vs 1.11 × 10 9 /L, respectively, p < 0.0001) and C-reactive protein (mean 31.5 vs 5.8 mg/L, respectively, p < 0.0001).Overall survival at 1 month was 79.5% (95% CI 68.7–90.3). Oxygen-support requirements improved and overall mortality was 13.6%. Confirmation of the efficacy of canakinumab for Covid-19 warrants further study in randomized controlled trials.
【초록키워드】 Treatment, Efficacy, COVID-19 pneumonia, therapy, Randomized controlled trials, Prospective Study, Diagnosis, C-reactive protein, oxygen, clinical outcomes, Clinical outcome, improvement, lymphocyte, Cohort, survival, Viral, Patient, Swab, canakinumab, Absolute lymphocyte count, administration, observation, 95% CI, significant differences, overall mortality, confirmation, median time, immunomodulating agents, oxygen support, Effect, duration of hospitalization, carried, died, treated, discharged, Significant, baseline, immunomodulating agent, IQR, PaO, patients hospitalized, 【제목키워드】 Patient, interleukin-1β,